Circio Holding ASA Logo

Circio Holding ASA

Developing circular RNA vector tech and immunotherapies for gene and cell therapies.

CRNA | OL

Overview

Corporate Details

ISIN(s):
NO0012858564 (+5 more)
LEI:
5967007LIEEXZXFYNS31
Country:
Norway
Address:
Vollsveien 19, 1366 Lysaker
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Circio Holding ASA is a biotechnology company developing novel circular RNA (circRNA) and immunotherapy medicines. The company's strategic focus is on its proprietary circRNA vector expression technology, designed to enhance the efficacy and safety of next-generation gene and cell therapies. Circio aims to establish a leading position in deploying circRNA for treating genetic diseases and other difficult-to-treat conditions. Its development platform, circVec, has shown the potential for substantially increased protein expression compared to conventional mRNA-based vectors. The company's pipeline includes both its circRNA gene therapy platform and clinical-stage immune-oncology candidates.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-03 08:13
Major Shareholding Notification
Corr: Atlas Holdings for CIRCIO
English 762 bytes
2025-10-30 11:02
Major Shareholding Notification
Corr: Atlas Holdings for CIRCIO
English 743 bytes
2025-10-30 08:04
Major Shareholding Notification
Atlas Holdings for CIRCIO
English 744 bytes
2025-10-23 15:23
Major Shareholding Notification
Flaggmelding fra Høse AS
Norwegian 816 bytes
2025-10-23 11:02
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 1.1 KB
2025-10-22 11:27
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 1.1 KB
2025-10-20 10:33
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 1.1 KB
2025-10-19 21:45
Share Issue/Capital Change
Circio Holding ASA Bond conversion and additional trading restrictions
English 3.7 KB
2025-10-17 16:39
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 3.0 KB
2025-10-15 11:14
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 3.0 KB
2025-10-08 07:00
Regulatory News Service
Circio presents comprehensive circVec in vivo data package demonstrating 40-fol…
English 6.2 KB
2025-10-06 12:07
Share Issue/Capital Change
Circio Holding ASA: Requested Conversion of Convertible Bonds
English 2.8 KB
2025-10-01 16:55
Prospectus
Circio Holding ASA Approval and publication of prospectus for potential futur…
English 3.0 KB
2025-10-01 07:00
Regulatory News Service
Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025
English 3.7 KB
2025-09-09 09:53
Share Issue/Capital Change
Circio Holding ASA: Registration of share capital increase following conversion…
English 2.5 KB

Automate Your Workflow. Get a real-time feed of all Circio Holding ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Circio Holding ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Circio Holding ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America
CNTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.